Cencora, Inc. (NYSE:COR - Free Report) - Research analysts at Zacks Research increased their Q2 2026 earnings estimates for Cencora in a research note issued on Wednesday, May 28th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will earn $4.78 per share for the quarter, up from their previous forecast of $4.45. The consensus estimate for Cencora's current full-year earnings is $15.37 per share. Zacks Research also issued estimates for Cencora's Q1 2027 earnings at $4.17 EPS and Q2 2027 earnings at $5.26 EPS.
Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Cencora's revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.80 EPS.
A number of other research firms have also issued reports on COR. UBS Group upped their target price on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Citigroup raised their target price on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. Bank of America raised their price objective on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Finally, Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $274.00 to $337.00 in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and a consensus price target of $306.91.
View Our Latest Report on Cencora
Cencora Price Performance
Shares of NYSE:COR traded down $0.49 on Monday, hitting $291.58. The company had a trading volume of 1,368,114 shares, compared to its average volume of 1,724,692. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The company has a market cap of $56.52 billion, a PE ratio of 41.48, a PEG ratio of 1.31 and a beta of 0.60. Cencora has a 52-week low of $218.65 and a 52-week high of $309.35. The business has a 50 day moving average of $285.24 and a 200 day moving average of $259.08.
Cencora Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. Cencora's dividend payout ratio (DPR) is 25.52%.
Insider Transactions at Cencora
In related news, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now directly owns 14,665 shares in the company, valued at approximately $3,934,326.20. This represents a 21.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares of the company's stock, valued at $89,027,442.53. The trade was a 4.41% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 40,253 shares of company stock worth $11,102,417 in the last three months. 10.80% of the stock is currently owned by company insiders.
Institutional Trading of Cencora
A number of hedge funds have recently made changes to their positions in the company. Net Worth Advisory Group grew its holdings in Cencora by 1.4% during the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock valued at $736,000 after purchasing an additional 36 shares in the last quarter. Obermeyer Wealth Partners grew its stake in shares of Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock valued at $758,000 after acquiring an additional 36 shares in the last quarter. Cromwell Holdings LLC increased its position in shares of Cencora by 9.5% during the first quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock worth $125,000 after acquiring an additional 39 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC increased its position in shares of Cencora by 2.7% during the first quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,565 shares of the company's stock worth $435,000 after acquiring an additional 41 shares during the last quarter. Finally, Whittier Trust Co. lifted its stake in shares of Cencora by 0.6% in the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after acquiring an additional 44 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.
About Cencora
(
Get Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
